Retina

Additional previous surgeries and the duration of the SO tamponade had little or no impact

Veeral Sheth, MD, MBA, FASRS, FACS, discusses outcomes from the Phase 1 HELIOS trial

New research and EURETINA highlights from the director of the "underdog" eye clinic

How retinal imaging can provide clinicians a deeper understanding of myopia

Yousif Subhi, MD, PhD, discusses his Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC"

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

The CHMP will recommend SB15, biosimilar to aflibercept (Eylea), for marketing authorisation by the European Commission

Research findings from Moorfields Eye Hospital also indicate SDD and drusen differ in many factors related to stroke risk

We spoke with Andrea Govetto, MD, PhD, winner of the inaugural Ramin Tadayoni Award at EURETINA

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

Researchers in Portugal investigated Usher syndrome, Senior-Loker syndrome and other ciliopathies

Why having a set process for diagnostic imaging is crucial to patient outcomes

Zhang’s journey as the first retina optometrist in Colorado

Bothnia Dystrophy generally presents during early childhood; patients have night blindness, progressive visual loss, and subsequent legal blindness.

A case series illuminates neuro-ophthalmologic manifestations, retinal vascular involvement and other pathologies

The research team used spectral-domain OCT and OCT angiography imaging to study the changes in the retinal microvasculature in patients

Dr Margaret A. Chang shares data on the port delivery system with ranibizumab, and her strategy for making the most of conferences

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for Aflibercept 8 mg and 2 mg.

The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

Retina is a rapidly advancing field with promising research, technology, and treatment areas. Two stand out as particularly exciting.

Researchers at the Karolinska Institute continue to investigate whether gene therapy can improve vision in people with Bothnia dystrophy, a form of hereditary blindness, prevalent in the region Västerbotten in Sweden.

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular degeneration at the Retina Society 57th Annual Scientific Meeting in Lisbon, Portugal.

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 clinical trial results for ONL-1204 for rhegmatogenous retinal detachment from the Retina Society meeting being held this year in Lisbon, Portugal.

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the 12-month outcomes of the FARETINA and FARWIDE studies from the Retina Society meeting being held this year in Lisbon, Portugal.